Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicentre retrospective study of 110 patients-Reference-Cited by-同舟云学术

Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicentre retrospective study of 110 patients

Published:2024-01-25 Issue:5 Volume:190 Page:771-773
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Grolleau Chloé¹^ORCID,Walter-Petrich Anouk²^ORCID,Dupin Nicolas³^ORCID,Chanal Johan³,Zehou Ouidad⁴^ORCID,Montlahuc Claire²,Baroudjian Barouyr¹^ORCID,Da Meda Laetitia¹^ORCID,Resche-Rigon Matthieu²^ORCID,Le Cleach Laurence⁴⁵^ORCID,Lebbé Céleste¹^ORCID

Affiliation:

1. Université Paris Cité, Dermato-Oncology and CIC AP-HP Hôpital Saint-Louis , INSERM U976, Paris , France

2. Biostatistics and Medical Information Department, AP-HP Saint-Louis Hospital , Paris , France

3. Department of Dermatology, AP-HP Cochin Hospital-Université Paris Cité , Institut Cochin INSERM U1016, Paris , France

4. Department of Dermatology, AP-HP Henri Mondor Hospital , Créteil , France

5. ER EpiDermE, Université Paris Est Créteil , Créteil, F-94010 , France

Abstract

Although systemic treatments are warranted in aggressive forms of classic and endemic Kaposi sarcomas (KS), therapeutic guidelines are lacking for those nonimmunodeficient subtypes. In this retrospective multicentre study, we showed that paclitaxel, liposomal doxorubicin and low-dose interferon had good overall response rates for nonimmunodeficient KS with acceptable tolerance profiles. In addition, we highlighted the aggressiveness of endemic KS compared with classic KS with a higher risk of dissemination and response depletion as progression proceeded.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae032/56956421/ljae032.pdf

Reference8 articles.

1. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy;Cianfrocca;Cancer,2010

2. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi’s sarcoma: a multicenter study;Di Lorenzo;J Invest Dermatol,2008

3. Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC);Lebbe;Eur J Cancer,2019

4. Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma: a retrospective study of 58 patients;Tourlaki;J Dermatolog Treat,2020

5. Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi’s sarcoma; retrospective analysis of three German centers;Kreuter;Cancer Invest,2005